Is BioLineRx Ltd. (BLRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 120.9% / 30% | 157.3% / 30% | 31.1% / 30% | 6.29% / 5% | ✗ NOT HALAL |
| DJIM | 120.9% / 33% | 157.3% / 33% | 31.1% / 33% | 6.29% / 5% | ✗ NOT HALAL |
| MSCI | 38.7% / 33% | 50.3% / 33% | 9.9% / 33% | 6.29% / 5% | ✗ NOT HALAL |
| S&P | 120.9% / 33% | 157.3% / 33% | 31.1% / 33% | 6.29% / 5% | ✗ NOT HALAL |
| FTSE | 38.7% / 33% | 50.3% / 33% | 9.9% / 50% | 6.29% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 80.5% | |
| Operating Margin | -1745.4% | |
| Net Margin | -99.6% | |
| Return on Equity (ROE) | -11.0% | |
| Return on Assets (ROA) | -16.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$44M |
| Free Cash Flow | -$44M |
| Total Debt | $15M |
| Debt-to-Equity | 43.5 |
| Current Ratio | 2.0 |
| Total Assets | $39M |
Price & Trading
| Last Close | $2.39 |
| 50-Day MA | $2.81 |
| 200-Day MA | $3.52 |
| Avg Volume | 15K |
| Beta | 0.5 |
|
52-Week Range
$2.28
| |
About BioLineRx Ltd. (BLRX)
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioLineRx Ltd. (BLRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioLineRx Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioLineRx Ltd.'s debt ratio?
BioLineRx Ltd.'s debt ratio is 120.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 38.7%.
What are BioLineRx Ltd.'s key financial metrics?
BioLineRx Ltd. has a market capitalization of $11M, trailing P/E ratio of inf, and revenue of $29M. The company maintains a gross margin of 80.5% and a net margin of -99.6%. Return on equity stands at -11.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.